An international working group of experts in myelodysplastic syndromes proposed the recognition of the SF3B1 variant as a distinct nosologic entity based on the presence of a non-inheritable genetic mutation that causes the disease.
Researchers suggested that treatment-free remission may be successfully obtained with an effector-suppressor score which is calculated using absolute natural killer cells, FoxP3+ regulatory T cells, and monocytic myeloid-derived suppressor cells.
The oncology hematologist spoke about the guidelines she and her colleagues outlined regarding treating patients with hematologic malignancies during the COVID-19 pandemic.
The FDA granted orphan drug designation to Ascentage Pharma’s HQP1351 for the treatment of chronic myeloid leukemia.
The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in adult patients with newly diagnosed or relapsed/refractory multiple myeloma.
Data from the phase III REACH2 study indicated that ruxolitinib therapy led to significant improvements in efficacy outcomes in patients with steroid-refractory acute graft-versus-host disease.
The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic.
Mount Sinai Health System announced that they will be using the allogeneic stem cell therapy remestemcel-L in patients with COVID-19, and have already tested the therapy in 10 patients.
Multiple studies designed to evaluate chimeric antigen receptor (CAR) T-cell therapies in various hematologic malignancies appeared to show promise at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orland
This study indicated that caregivers saw improved quality of life, reduced caregiving burden, lower anxiety and depression symptoms, and improved self-efficacy and coping skills having received psychosocial intervention.